Perforated primary adenocarcinoma of the colon with choriocarcinoma differentiation treated with targeted colorectal cancer chemotherapy: a case report

Colorectal choriocarcinoma is a rare condition with a poor prognosis, and no standard chemotherapy regimen has been established. A combination of cetuximab, encorafenib, and binimetinib as adjuvant chemotherapy may be effective for colorectal choriocarcinoma. This treatment approach has not been pre...

Full description

Saved in:
Bibliographic Details
Published inAME case reports Vol. 9; p. 73
Main Authors Ishimaru, Naoki, Tagami, Takashi, Yamasaki, Misako, Niwa, Kazuya
Format Journal Article
LanguageEnglish
Published China AME Publishing Company 06.05.2025
Subjects
Case Report
Case report
chemotherapy
choriocarcinoma
colorectal choriocarcinoma
colorectal adenocarcinoma
Online AccessGet full text

Cover

More Information
Summary:Colorectal choriocarcinoma is a rare condition with a poor prognosis, and no standard chemotherapy regimen has been established. A combination of cetuximab, encorafenib, and binimetinib as adjuvant chemotherapy may be effective for colorectal choriocarcinoma. This treatment approach has not been previously reported for this rare malignancy. We describe the case of a 59-year-old woman who underwent right hemicolectomy for a transverse colon perforation and was diagnosed with primary colorectal adenocarcinoma with choriocarcinoma differentiation. Adjuvant chemotherapy with folinic acid, fluorouracil, and oxaliplatin (FOLFOX) and bevacizumab was administered for colorectal adenocarcinoma, but disease progression was observed. The patient had a V600E mutation, tested negative for human chorionic gonadotropin (hCG), and was switched to a combination of encorafenib, cetuximab, and binimetinib. The treatment response was monitored through regular imaging studies and tumor marker measurements. The patient has been alive for 34 months with no metastases or recurrence, and with continued reduction in the size of the lymph nodes and peritoneal lesions. Standard chemotherapy for the treatment of choriocarcinoma and colorectal adenocarcinoma has been applied to colorectal choriocarcinoma. In patients with a V600E mutation and decreased hCG levels, a combination of encorafenib, cetuximab, and binimetinib may be a useful chemotherapeutic option when treating patients with colorectal choriocarcinoma.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
Contributions: (I) Conception and design: N Ishimaru; (II) Administrative support: K Niwa; (III) Provision of study materials or patients: N Ishimaru, M Yamasaki; (IV) Collection and assembly of data: N Ishimaru, T Tagami; (V) Data analysis and interpretation: N Ishimaru, T Tagami; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.
ISSN:2523-1995
2523-1995
DOI:10.21037/acr-24-252